Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

House dust mite allergy immunotherapy tablet - Stallergenes Greer plc

Drug Profile

House dust mite allergy immunotherapy tablet - Stallergenes Greer plc

Alternative Names: Actair; House dust mite allergy immunotherapy - Stallergenes Greer plc; House dust mite SLIT; House dust mite sublingual immunotherapy; Oralair Mites; S-524101; STAGR 320; STG 320

Latest Information Update: 10 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stallergenes SA
  • Developer Shionogi; Stallergenes Greer plc
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Perennial allergic rhinitis

Most Recent Events

  • 20 Nov 2018 Stallergenes announces intention to submit BLA to the US FDA as well as for additional marketing authorizations in European and international markets for Perennial allergic rhinitis
  • 20 Nov 2018 Efficacy data from a phase III trial in Perennial allergic rhinitis released by Stallergenes Greer
  • 21 Jun 2018 Stallergenes Greer completes a phase III trial for Perennial allergic rhinitis (In adolescents, In adults) in USA, France, Germany, Belgium, Slovakia, Czech Republic, Bulgaria, Poland and Spain (PO, Sublingual) (NCT02443805) (EudraCT2014-004223-46)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top